Priya Rastogi

22.0k citations
142 papers · 6.7k indexed · 4 hit papers · h-index 34

Impact in

    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics
  • Oncology top 0.2%
    • HER2/EGFR in Cancer Research
    • Cancer Treatment and Pharmacology

Papers in

    • Breast Cancer Treatment Studies 64
    • HER2/EGFR in Cancer Research 62
    • Cancer Treatment and Pharmacology 45
    • Cancer Risks and Factors 12

Priya Rastogi

139 papers receiving 6.6k citations

Hit Papers

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial 2018 · 516 citations
51620052026201220194008001.2k

Peers

Priya Rastogi
Comparison fields: 5 of 119
  • Cancer Research 3.5k
  • Oncology 4.8k
  • Pathology and Forensic Medicine 990
  • Radiology, Nuclear Medicine and Imaging 1.2k
  • Pulmonary and Respiratory Medicine 1.4k
Replace Milvia Zambetti with:
Milvia Zambetti Italy
Marc Espié France
Grazia Arpino Italy
Aron Goldhirsch Italy
Shaheenah Dawood United Arab Emirates
Gilles Romieu France
Eva Ciruelos Spain
Jacques Bonneterre France
Henri Roché France
Giulia Bianchi Italy
Priya Rastogi relative to Milvia Zambetti Italy Milvia Zambetti's profile →
Citations per field
00.5×3.1×
Milvia Zambetti · 1×
Citations per year

Countries citing papers authored by Priya Rastogi

Since Specialization
Citations

This map shows the geographic impact of Priya Rastogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Priya Rastogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Priya Rastogi more than expected).

Fields of papers citing papers by Priya Rastogi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Priya Rastogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Priya Rastogi. The network helps show where Priya Rastogi may publish in the future.

Co-authors

The 25 scholars most cited alongside Priya Rastogi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Priya Rastogi Line = papers co-authored together Priya Rastogi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20243
2 20247
3 20245
4 202412
5 20231
6 20233
7 202311
8 202311
9 20234
10 20224
11 202112
12 201924
13 20177
14 201533
15
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140).
20157
16 2013261
17 201364
18
Targeting alternative pathways in HER2-positive breast cancer.
20102
19 201010
20
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31
Hit paper breakdown →
2005568

About Priya Rastogi

Priya Rastogi is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 142 papers that have together received 6.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (64 papers), HER2/EGFR in Cancer Research (62 papers), Advanced Breast Cancer Therapies (47 papers), Cancer Treatment and Pharmacology (45 papers), Estrogen and related hormone effects (18 papers), Cancer Risks and Factors (12 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and BRCA gene mutations in cancer (9 papers). The work is most often cited by research in Cancer Research (3.5k citations), Oncology (4.8k citations), Pathology and Forensic Medicine (990 citations), Radiology, Nuclear Medicine and Imaging (1.2k citations) and Pulmonary and Respiratory Medicine (1.4k citations). Priya Rastogi has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Charles E. Geyer, Norman Wolmark, Eleftherios P. Mamounas, Sandra M. Swain, André Robidoux, Victor G. Vogel, Soonmyung Paik, Louis Fehrenbacher, Richard G. Margolese and Harry D. Bear. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Breast Cancer Research and Treatment and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026